Research Translation
Innovation must align with overseas regulation, clinical needs, product standards and commercial viability.

For biopharma, medical device and healthtech companies, we connect Hong Kong establishment, regulatory readiness, policy resources, research translation and global market development.
Innovation must align with overseas regulation, clinical needs, product standards and commercial viability.
Registration, quality systems and healthcare promotion rules vary by market and continue to evolve.
Gaps in entity setup, people, tax, supply chain or cross-border structure compound cost and risk.
Companies need credible positioning, local partnerships and sustainable routes into overseas markets.
Business infrastructure and healthcare-specialist work advance together, reducing fragmented handoffs and duplicated effort.
Establish the operating and compliance foundation required for long-term growth in Hong Kong and target markets.
Purpose-built support for regulated healthcare markets with long timelines and specialist requirements.
Map innovation policies and funding pathways, prepare applications and match facilities, talent and specialist resources to healthcare R&D needs.
Build the corporate, tax and legal foundation, with pathway support for product access, IP, technical files and quality systems.
Coordinate office selection, talent recruitment, work visas, ODI and cross-border employment planning.
Localise healthcare brands, develop compliant content, connect channels and distributors, operate events and deploy MarTech.

Support customs, sample delivery, medical cold chain, event logistics and overseas after-sales operations.

Connect medical language expertise, university–industry co-creation, clinical exchange and academic collaboration.
Assess the product, current qualifications, target markets and resources; then define priorities, milestones and risks.
Coordinate entity setup, policy, innovation parks, people, finance, tax and cross-border structure.
Advance registration support, quality systems, IP, technical documentation and specialist language work.
Combine brand, channels, academic collaboration, supply chain and digital capabilities into a sustainable international growth loop.
The following anonymised examples illustrate service pathways only. They do not promise any approval, timeline or commercial outcome.

Local R&D team → innovation-park incubation → healthcare talent → cross-border supply chain → standards and qualification guidance.

Local registration support → IP strategy → brand system → hospital and university collaboration → academic credibility.
Jifan Technology grew from Jiyin Research Institute, founded in 2015. After a 2025 brand evolution and Hong Kong establishment, the team now focuses on compliance, market access, research translation and resource collaboration for healthcare companies.

We primarily support biopharma, medical device, diagnostics, medical imaging and related healthtech companies using Hong Kong as an international business hub.
Yes. Services can be scoped by business stage, but we begin with an end-to-end pathway review so that a local decision does not conflict with later compliance or market objectives.
Work is delivered, reviewed and billed by phase. Deliverables, scope boundaries and third-party costs are documented in the project proposal.
Timing depends on product classification, available technical files, target market and regulator feedback. After diagnosis, we provide assumption-based milestones rather than promising a fixed approval period.
Share your product type, current qualifications, target market and expected timing. We will arrange an initial market-entry diagnosis.
Tell us your product type, current qualifications and target market to receive an initial Hong Kong pathway and priority recommendation.
Book a Market-Entry Diagnosis